RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) is set to host its Investor & Analyst Day on September 20 in New York, where the company’s leadership and key opinion leaders (KOLs) will discuss the latest advancements and strategic plans. The event will spotlight ZTALMY® (ganaxolone) oral suspension CV, particularly its application in treating tuberous sclerosis complex (TSC).
Attendees can anticipate insights into the development program and commercial launch readiness of ZTALMY®, as well as updated data from the Phase 3 TrustTSC trial. Additionally, KOLs will share clinical insights and new data from the Phase 2 TSC trial, offering a comprehensive view of TSC’s burden and existing treatment challenges.
Marinus will also unveil plans to extend its clinical pipeline into other neurodevelopmental epilepsies, contingent on forthcoming topline data from the TrustTSC trial due in the fourth quarter of 2024. Notable speakers include CEO Scott Braunstein, M.D., and several other key executives, alongside distinguished KOLs like Dr. Mary Kay Koenig and Dr. Rajsekar R. Rajaraman. This event underscores Marinus’ commitment to advancing treatment options for rare neurological conditions and enhancing its market presence.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.